Skip to main content

Fall 41: Therapie – 73 Jahre, ♀, Prädiabetes, erhöhte Nüchternglukose, Nierenschädigung

  • Chapter
  • First Online:
  • 2277 Accesses

Zusammenfassung

Eine 73-jährige Patientin mit einer erhöhten Nüchternglukose, einem normalem HbA1c und normalem 2-Stunden-Wert im oGTT, aber Abfall der GFR und Zunahme der Albuminurie trotz einem mit ACE-Hemmer und Diuretikum sehr gut eingestellten Blutdruck, nach Ausschluss anderer Ursachen der Nierenschädigung, fragt, ob sie mit einem SGLT2-Inhibitor behandelt werden sollte. Was sagt die jetzige Studienlage?

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan KM, Barrett-Connor E, Watson K, Knowler WC, Horton ES, Diabetes Prevention Program Research G (2008) Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes care 31(12):2344–2348. https://doi.org/10.2337/dc08-0148

    Article  CAS  Google Scholar 

  • Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, Group AS (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244–252

    Article  Google Scholar 

  • Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research G (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379(9833):2243–2251. https://doi.org/10.1016/S0140-6736(12)60525-X

    Article  CAS  Google Scholar 

  • Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123(10):754–762

    Article  CAS  Google Scholar 

  • Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12(2):218–225

    CAS  PubMed  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, Investigators E-RO (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefan Kopf .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kopf, S. (2018). Fall 41: Therapie – 73 Jahre, ♀, Prädiabetes, erhöhte Nüchternglukose, Nierenschädigung. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-55972-7_41

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-55971-0

  • Online ISBN: 978-3-662-55972-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics